Failed MyVax Cancer Vaccine Trial Could Be Due To Active Comparator, Genitope Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm remains optimistic about the non-Hodgkin’s lymphoma vaccine due to a statistically significant increase in progression-free survival among MyVax responders.
You may also be interested in...
Sanofi/Oxford BioMedica To Present Positive Phase II Data For Cancer Vaccine TroVax At ASCO
Oxford BioMedica anticipates filing a BLA in 2009 for RCC.
Sanofi/Oxford BioMedica To Present Positive Phase II Data For Cancer Vaccine TroVax At ASCO
Oxford BioMedica anticipates filing a BLA in 2009 for RCC.
Pharmexa Pancreatic Cancer Vaccine Fails Phase III Study
Firm says it will continue enrolling another Phase III trial, with data expected in 2011.